Yin Yang 1 Deficiency in Skeletal Muscle Protects against Rapamycin-Induced Diabetic-like Symptoms through Activation of Insulin/IGF Signaling
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
SUMMARY Rapamycin and derivatives are mTOR inhibitors used in tissue transplantation and cancer therapy. A percentage of patients treated with these inhibitors develop diabetic-like symptoms but the molecular mechanisms are unknown. We show here that chronic rapamycin treatment in mice leads to insulin resistance with suppression of insulin/IGF signaling and genes associated within this pathway, such as IGFs, IRS1/2 and AKTs. Importantly, skeletal muscle-specific YY1 knockout mice were protected from rapamycin-induced diabetic-like symptoms. This protection was caused by hyperactivation of insulin/IGF signaling with increases in genes in this cascade that, in contrast to wild-type mice, were not suppressed by rapamycin. Mechanistically, rapamycin induced YY1 dephosphorylation and recruitment to promoters of insulin/IGF genes, which promoted interaction with the polycomb protein-2 corepressor. This was associated with H3K27 tri-methylation leading to decreases in gene expression and insulin signaling. These results have implications for rapamycin action in human diseases and biological processes, such as longevity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925
Self-citationRapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020 · cited 6×
“Furthermore, mTOR regulates glycolysis through hypoxia-inducible factor 1 alpha (HIF1a) (Düvel et al., 2010) and ketogenesis through peroxisome proliferator-activated receptor alpha (PPARa), possibly by regulating subcellular localization of the corepressor NCoR1 (Sengupta et al., 2010a).”
BackgroundInfluentialAbsence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677 · cited 2×
“…to what would be predicted based on the mTOR-activated S6K negative feedback on insulin signaling (Haruta et al., 2000; Sarbassov et al., 2005; Um et al., 2004), a percentage of patients treated with mTOR inhibitors develop a variety of diabetic-like symptoms, including glucose intolerance,…”
BackgroundResultKuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596 · cited 2×
“Pc2 is part of the PRC1 polycomb repressor complex that is sequentially recruited to chromatin promoter regions after the PRC2 complex, which contains the methyltransferase Ezh2 and catalyzes trimethylation of H3K27, an epigenetically repressive histone marker (Hansen et al., 2008; Kagey et al., 2003; Kuzmichev et al.…”
BackgroundBeausoleil, S. A., Villén, J., Gerber, S. A., Rush, J., & Gygi, S. P. (2006) · Nature Biotechnology · doi:10.1038/nbt1240 · Cited by 1,577
Self-citationmTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488
Self-citationDisordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093
Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806 · cited 2×
“Recently, several transcription factors including SREBP and HIF1a have been linked to mTOR activation (Brown et al., 2007; Düvel et al., 2010; Mauvoisin et al., 2007; Peng et al., 2002; Porstmann et al., 2008), but their involvement in the rapamycin-mediated metabolic dysregulation is unknown.”
BackgroundGarofalo, R. S., Orena, S. J., Rafidi, K., Torchia, A. J., Stock, J. L., Hildebrandt, A. L., Coskran, T., Black, S. C., Brees, D. J., Wicks, J. R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16885 · Cited by 726 · cited 1×
“Furthermore, AKT2-deficient mice display high plasma insulin, insulin resistance, and impaired ability to reduce glucose levels, a phenotype attributed to the impairment of insulin action in skeletal muscle and liver (Cho et al., 2001; Garofalo et al., 2003).”
BackgroundmTORC1 controls fasting-induced ketogenesis and its modulation by ageing
Sengupta, S., Peterson, T. R., Laplante, M., Oh, S., & Sabatini, D. M. (2010) · Nature · doi:10.1038/nature09584 · Cited by 646 · cited 4×
“Furthermore, mTOR regulates glycolysis through hypoxia-inducible factor 1 alpha (HIF1a) (Düvel et al., 2010) and ketogenesis through peroxisome proliferator-activated receptor alpha (PPARa), possibly by regulating subcellular localization of the corepressor NCoR1 (Sengupta et al., 2010a).”
BackgroundInfluentialBentzinger, C. F., Romanino, K., Cloëtta, D., Lin, S., Mascarenhas, J. B., Oliveri, F., Xia, J., Casanova, E., Costa, C. F., Brink, M., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.10.002 · Cited by 640 · cited 2×
“Next, we tested whether the metabolic effects of rapamycin in mice were occurring specifically throughmTORC1 using skeletal muscle-specific Raptor knockout mice (RamKO) (Bentzinger et al., 2008) and a different mTOR chemical inhibitor, Torin 2 (Liu et al.”
MethodSelf-citationHoude, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A. (2010) · Diabetes · doi:10.2337/db09-1324 · Cited by 456 · cited 3×
“For example, the liver would contribute through hepatic insulin resistance to uncontrolled higher rates of hepatic glucose production, as shown using hyperinsulinemic-euglycemic clamps in Figure S1E and as previously suggested in rats (Houde et al., 2010).”
BackgroundResultMitochondrial signaling, TOR, and life span
Schieke, S. M., & Finkel, T. (2006) · Biological Chemistry · doi:10.1515/bc.2006.170 · Cited by 106
Cited by
Mechanisms regulating skeletal muscle growth and atrophy
Schiaffino, S., Dyar, K. A., Ciciliot, S., Blaauw, B., & Sandri, M. (2013) · The FEBS Journal · doi:10.1111/febs.12253 · Cited by 1,492
Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy
Yoshida, T., & Delafontaine, P. (2020) · Cells · doi:10.3390/cells9091970 · Cited by 714
Fleishman, J. S., & Kumar, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01811-6 · Cited by 544
Mitochondrial homeostasis: The interplay between mitophagy and mitochondrial biogenesis
Palikaras, K., & Tavernarakis, N. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.01.021 · Cited by 429
Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Shivaswamy, V., Boerner, B., & Larsen, J. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1084 · Cited by 328
Metadata
- Authors
- Blättler, S. M., Cunningham, J. T., Verdeguer, F., Chim, H., Haas, W., Liu, H., Romanino, K., Rüegg, M. A., Gygi, S. P., Shi, Y., & Puigserver, P.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 15
- Issue
- 4
- Pages
- 505-517
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W1974935593
- Cited by
- 105
- References
- 16
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.